Retatrutide Overview
Retatrutide, with its compound code LY-3437943, is an experimental peptide drug targeting obesity. It functions as a triple hormone receptor agonist, influencing metabolic regulation and appetite control. Notably effective in weight reduction, it’s a pioneering approach in obesity management, offering potential improvements in metabolic health.
Product Details
- Structure:Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg
- Molecular Formula:C101H152N28O22S2
- Molecular Weight:64 g/mol
- PubChem SID:255386757
- CAS Number:1627580-64-6
- Synonyms:Mitochondrial open reading frame of the 12S rRNA-c, MT-RNR1
Research Highlights
- Retatrutide & Weight Loss:In a phase 2 trial, participants saw a mean weight reduction of 18% at 24 weeks and 24% at 48 weeks, surpassing placebo results.
- Retatrutide & Glucose Metabolism:As a triple agonist, it positively influences glucose metabolism, beneficial in managing obesity-related impaired glucose regulation.
- Retatrutide & Dose Response:The trial demonstrated a dose-response relationship, with higher doses leading to greater weight reduction, highlighting its customizable potential for obesity treatment.
- Important Notices:
- This product is sold for scientific research purposes only.
